Key result
The J-CTO score was not an independent predictor of major adverse cardiovascular events (HR 1.018; 95% CI 0.728-1.424; P=0.917) in patients undergoing difficult in-stent chronic total occlusion PCI.
Why the study?
The impact of the J-CTO score on in-stent chronic total occlusion PCI outcomes had not been clearly determined.
Does the J-CTO score predict technical success and long-term MACE in patients undergoing difficult in-stent chronic total occlusion PCI?
Cohort (n=474)
Does the J-CTO score predict technical success and long-term MACE in patients undergoing difficult in-stent chronic total occlusion PCI?
The J-CTO score does not predict technical success or long-term outcomes in difficult in-stent chronic total occlusion PCI, whereas specific anatomical factors and long-term DAPT are more relevant.
J-CTO score should not guide IS-CTO PCI decisions; leaves open need for dedicated predictors in this population.
AIM: The purpose of this study was to investigate the impact of J-CTO (Multicenter Chronic Total Occlusion Registry of Japan) score on in-stent chronic total occlusion (IS-CTO) percutaneous coronary intervention (PCI). METHODS: A retrospective data collection was conducted on 474 patients undergoing a difficult IS-CTO PCI from January 2015 to December 2018. The primary endpoint (major adverse cardiovascular events [MACE]) consisted of target-vessel myocardial infarction (MI), cardiac death or ischemia-driven target-vessel revascularisation (TVR) at follow-up. The cut-off points were estimated by the Youden index. RESULTS: The overall procedural success rate was 77.6%. On multivariable analysis, factors including proximal bending (beta coefficient [β] = 3.465), tortuosity (β = 3.064), stent under expansion (β = 3.109) and poor distal landing zone (β = 1.959) were associated with technical failure via antegrade approach but not the J-CTO score (OR = 0.632; 95% CI [0.352-1.134]; P = .124). After a median follow-up of 30 months (interquartile range: 17-42 months), multivariable analysis revealed that receiving >18 months of dual antiplatelet therapy (DAPT) was an independent predictor of decreased risk of MACE (HR: 2.690; 95% CI: 1.346-5.347; P = .005). But the J-CTO score was not an independent predictor of MACE (HR: 1.018; 95% CI: 0.728-1.424; P = .917). CONCLUSIONS: J-CTO score system is not a helpful tool to predict the technical success of difficult IS-CTO PCI via antegrade approach, nor does it correlate with long-term outcomes in patients undergoing IS-CTO PCI. Nevertheless, factors associated with technical failure include proximal bending of ≥30 degrees, under expansion of ≥10 mm, moderate or severe tortuosity (bending) ≥20 and poor distal target. Long-term DAPT therapy contributes significantly to decreased MACE.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2021) conducted a cohort in In-stent chronic total occlusion (IS-CTO) (n=474). J-CTO score was evaluated on Major adverse cardiovascular events (MACE) consisting of target-vessel myocardial infarction, cardiac death or ischemia-driven target-vessel revascularisation (HR 1.018, 95% CI 0.728-1.424, p=0.917). The J-CTO score was not an independent predictor of major adverse cardiovascular events (HR 1.018; 95% CI 0.728-1.424; P=0.917) in patients undergoing difficult in-stent chronic total occlusion PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: